Pms42 - Secukinumab Versus Adalimumab for the Treatment of Ankylosing Spondylitis: A 52-Week Cost Per Responder Analysis From the Portuguese Payer Perspective
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1756
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV